Bionano Genomics, Inc. reports developments in genome analysis solutions built around optical genome mapping (OGM), diagnostic services, software and nucleic acid extraction technologies. Company updates commonly address OGM applications in cytogenetics, rare disease research, hematologic malignancies, reproductive disorders and other genomic-analysis workflows, including published studies comparing OGM with karyotyping, FISH, chromosomal microarrays, next-generation sequencing and long-read sequencing.
Recurring news also covers financial results, revenue outlooks, scientific-meeting presentations, Bionano Symposium activity, use of VIA™ software, the Ionic® system and Bionano Laboratories diagnostic testing services. Governance updates include board and executive leadership changes at the Nasdaq-listed life sciences instrumentation company.
Bionano Genomics (BNGO) will actively participate in the AGBT General Meeting 2022 in Orlando, Florida, from June 6-9. Dr. Alka Chaubey, the chief medical officer, will deliver a spotlight presentation on June 8, addressing the integration of Optical Genome Mapping (OGM) and Next Generation Sequencing (NGS) for enhanced genome analysis. Bionano is also a Bronze Sponsor and will host an evening reception, unveiling a partnership with Ignite Worldwide to promote equity in STEM. Attendees can explore live demonstrations of the Saphyr system and NxClinical software.
Bionano Genomics (Nasdaq: BNGO) announced the publication of a peer-reviewed study demonstrating the efficacy of optical genome mapping (OGM) in identifying genetic aberrations in pediatric acute myeloid leukemia (AML). Conducted by researchers at University Hospital Essen, the study analyzed samples from 24 patients, revealing that OGM detected significantly more structural variants (SVs) than traditional methods like FISH. Notably, 32 previously unknown variants were identified, with one being a high-risk marker exclusive to OGM. This research highlights OGM's potential in tracking minimal residual disease (MRD) markers crucial for treatment management.
Bionano Genomics, Inc. (BNGO) will participate virtually in the 2022 H.C. Wainwright Global Investment Conference. The presentation will be available on-demand starting May 24, 2022, at 7:00 a.m. Eastern Time. Erik Holmlin, PhD, President and CEO, will provide a company overview. Bionano specializes in optical genome mapping solutions and diagnostic software, aiming to transform genome analysis in research and medicine. Interested individuals can register for the conference and access the presentation online.
Bionano Genomics (BNGO) is showcasing its full range of cytogenetic research solutions at the American Cytogenomics Conference (ACC) from May 15-18, 2022, in Hilton Head, South Carolina. This year, Bionano exhibits its Optical Genome Mapping (OGM) solutions, NxClinical software, and laboratory services. Six scientific presentations will detail the applications of OGM in prenatal, postnatal testing, and cancer research. The company also plans to host a user spotlight event at Augusta University, highlighting its commitment to advancing genomic analysis.
Bionano Genomics (BNGO) announced the publication of a study from The First Affiliated Hospital of Zhengzhou, Central China's largest hospital, showcasing the advantages of optical genome mapping (OGM) for structural variant analysis. Conducted by Dr. Xiangdong Kong, the study demonstrated OGM's effectiveness in detecting chromosome balanced translocations compared to traditional methods like karyotype analysis and FISH. This innovative approach could enhance preimplantation genetic testing and address recurrent pregnancy loss, an area of significant unmet need in fertility treatment.
Bionano Genomics reported 80% year-over-year revenue growth in Q1 2022, achieving all ELEVATE! milestones. Total revenue reached $5.7 million, despite a decline in gross margin to 15% from 33% in Q1 2021. The company expanded its Saphyr system installations to 176, a 64% increase year-over-year. With a strong balance sheet of $216.5 million in cash, Bionano remains on track to meet its annual revenue guidance of $24 million to $27 million. The Q1 conference call is scheduled for May 5, 2022, at 4:30 PM ET.
Bionano Genomics (Nasdaq: BNGO) announced a peer-reviewed publication in Nature detailing the NeuroSCORE software, aimed at analyzing complex genetic conditions like autism spectrum disorder (ASD) and epilepsy. This innovative tool identifies over 1,000 genes affecting neurodevelopment, enhancing diagnostics and therapeutic research. The study scored over 18,000 genes based on various data models to prioritize those linked to neurodevelopmental diseases. CEO Erik Holmlin expressed optimism that NeuroSCORE will facilitate the interpretation of unknown genetic variants.
Bionano Genomics (BNGO) has announced a conference call and live webcast to discuss its Q1 2022 financial results on May 5, 2022, at 4:30 p.m. ET. This event aims to highlight the company's recent corporate progress in genome analysis solutions, which support researchers and clinicians in biology and medicine. Bionano's offerings include Optical Genome Mapping (OGM) solutions, diagnostic testing through Lineagen, and BioDiscovery software for genomic data analysis.
TwinStrand Biosciences has appointed Goran Pljevaljcic, Ph.D., as Chief Commercial Officer. He brings over 20 years of experience in the genomics industry, including significant roles at Bionano Genomics (NASDAQ: BNGO). This leadership change aims to strengthen the company's commercial strategy as it expands its high-resolution duplex sequencing offerings, which enhance the detection of low-frequency genomic variants. Dr. Pljevaljcic's expertise is expected to accelerate the deployment of these technologies for clinical applications, improving healthcare outcomes.
Bionano Genomics, Inc. (Nasdaq: BNGO) recently announced the issuance of two new US patents, No. 11,291,999 and No. 11,292,713, by the United States Patent and Trademark Office on April 5, 2022. The ‘999 patent focuses on a novel apparatus for minimizing biopolymer aggregation in nanochannels, enhancing DNA loading cycles. The ‘713 patent expands patent protection for optical genome mapping technology, detailing methods for detecting genomic variants. These patents bolster Bionano's intellectual property portfolio, supporting its goal of advancing genomic insights in clinical research.